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Pathobionts play a critical role in disease develop-
ment, but the immune mechanisms against patho-
bionts remain poorly understood. Here, we report a
critical role for interleukin-22 (IL-22) in systemic pro-
tection against bacterial pathobionts that translocate
into the circulation after infection with the pathogen
Clostridiumdifficile. InfectionwithC. difficile induced
IL-22, and infected Il22/ mice harbored high
numbers of pathobionts in extraintestinal organs
despite comparable pathogen load and intestinal
damage in mutant and wild-type mice. Pathobionts
exhibited increased resistant against complement-
mediated phagocytosis, and their intravenous
administration resulted in high animal mortality. Se-
lective removal of translocated commensals rescued
Il22/ mice, and IL-22 administration enhanced the
elimination of pathobionts. Mechanistically, IL-22
augmented bacterial phagocytosis by increasing
the expression and bacterial binding of complement
C3. Our study demonstrates an unexpected role for
IL-22 in controlling the elimination of pathobionts
that enter the systemic circulation through the regu-
lation of the complement system.
INTRODUCTION
The intestine of humans and animals harbors diverse microbial
species that provide numerous benefits to their hosts (Kamada
et al., 2013; Round and Mazmanian, 2009). However, the gut
microbiota also includes potentially virulent species, called path-
obionts, that can cause disease when intestinal homeostasis is
disrupted, particularly in immunocompromised hosts (Chow
and Mazmanian, 2010; Kamada et al., 2013). Indeed, disruption
of the healthy microbiota by several mechanisms, including anti-
biotic treatment, results in dysbiosis, which can lead to the accu-
mulation of pathobionts and disease (Kamada et al., 2013; Pham620 Immunity 41, 620–632, October 16, 2014 ª2014 Elsevier Inc.and Lawley 2014). However, the mechanisms whereby patho-
bionts give rise to disease remain poorly understood. Clos-
tridium difficile is a Gram-positive anaerobic bacterium that
overgrows during dysbiosis in patients who have received
broad-spectrum antibiotics and causes infectious diarrhea and
pseudomembranous colitis (Carroll and Bartlett 2011). The
severity ofC. difficile infection varies frommild diarrhea to septic
shock and multiple organ failure, associated with high mortality
(Eaton and Mazuski, 2013; Sunenshine and McDonald, 2006).
Moreover, even after treatment with antibiotics such as vanco-
mycin and metronidazole, which eradicate C. difficile, 7% of
patients will still die fromC. difficile infection (Carroll and Bartlett,
2011). Although the cause of severe complications and mortality
associated with C. difficile infection remains poorly understood,
animal studies suggest that commensal bacteria contribute to
disease severity. For example, after C. difficile infection, mice
lacking interleukin-1b (IL-1b), inflammasome components, or
the innate immune receptor Nod1 exhibit high mortality associ-
ated with impaired neutrophil recruitment to areas of intestinal
damage and increased translocation of commensal bacteria
(Hasegawa et al., 2011; Hasegawa et al., 2012). Thus, translo-
cated commensal bacteria might contribute to C. difficile-
infection-induced mortality, but the mechanisms by which
commensal bacteria from the intestine accumulate in extraintes-
tinal tissues and the immune factors that protect the host against
their accumulation remain largely unknown.
IL-22, a cytokine produced by RORgt+ innate lymphoid cells, T
helper 17 (Th17) cells, Th22 cells, and gd T cells, has been impli-
cated in the control of commensal bacteria in the intestine (Son-
nenberg et al., 2011). Secretion of IL-22 from intestinal immune
cells is regulated by IL-23 and IL-1b, the latter of which is pro-
duced largely via the inflammasome (Sutton et al., 2009). IL-22
enhances the expression of antimicrobial proteins that limit the
association between certain intestinal bacteria and the epithe-
lium (Brandl et al., 2007; Zheng et al., 2008). Furthermore, IL-
22 regulates the repair of damaged epithelium and maintains
homeostasis of the microbiota (Sa et al., 2007, Zheng et al.,
2008). Moreover, IL-22 plays an important role in host protection
against enteropathogens, such as Citrobacter rodentium (Aujla
et al., 2008; Basu et al., 2012; Satoh-Takayama et al., 2008;
Schulz et al., 2008). Unlike C. difficile infection, which induces
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lium-damaging toxins A and B (TcdA and TcdB, respectively)
(Kuehne et al., 2010), intestinal disease triggered by
C. rodentium develops more slowly, and pathogen clearance is
dependent on acquired immunity (Mundy et al., 2005). Here,
we report that IL-22-deficient mice exhibited increased mortality
after oral infection withC. difficile, andmice were rescued by se-
lective antibiotic treatment that removed commensal bacteria,
but not C. difficile. The intestinal burden of C. difficile and the
extent of intestinal damage were not altered in infected Il22/
mice. Instead, IL-22 enhanced the expression of complement
C3, which contributed to the clearance of specific pathobionts
from peripheral organs. Hence, our study underscores a critical
role for IL-22 in protecting the host beyond the intestine by facil-
itating the systemic clearance of intestinal pathobionts.
RESULTS
IL-22-Deficient Mice Are More Susceptible to C. difficile
Infection
To assess the role of IL-22 in C. difficile-induced colitis, we in-
fected antibiotic-treated mice with the pathogen that recapitu-
lates many of the disease features observed in humans (Chen
et al., 2008; Hasegawa et al., 2011). We detected increased pro-
duction of IL-22 in the intestine, lung, and liver of mice 24 hr after
infection with C. difficile (Figure 1A). We also detected marginal
induction of IL-17 in cecum afterC. difficile infection (Figure S1A,
available online). To assess the source of increased IL-22, we in-
fected Rag1/ mice, which lack T and B cells, and found that
increased IL-22 amounts afterC. difficile infection were indepen-
dent of RAG1, whereas no significant IL-17 induction was
detected in the absence of RAG1 (Figures S1A and S1B). This
suggests that the source of increased IL-22 is innate cells, but
not mature T and B cells, including Th17, Th22, and gd T cells.
To investigate the role of IL-22 in host protection during
C. difficile infection, we assessed the survival of Il22/ mice
after C. difficile infection and found strikingly higher mortality
rates in Il22/ mice than in wild-type (WT) mice (Figure 1B).
We also found no significant impact of RAG1 deficiency on
mouse survival afterC. difficile infection (Figure S1C), suggesting
that T-cell-derived cytokines, including IL-17 in this case, are
dispensable for protection againstC. difficile infection. To under-
stand the cause of increasedmortality in Il22/mice associated
with C. difficile infection, we analyzed tissue histology and found
a similar degree of intestinal damage, including epithelial disrup-
tion, submucosal edema, and infiltration of inflammatory cells
(including neutrophils), in Il22/ and WT mice 3 days after
C. difficile infection (Figures 1C–1E). Consistently, flow cytomet-
ric analysis showed similar numbers of neutrophils (CD11b+
Ly6G+) and macrophages (CD11b+F4/80+) in the intestines of
Il22/ and WT mice 2 days after C. difficile infection (Figures
1F–1H). Additionally, Il22/ andWTmice produced comparable
amounts of CXCL1, a chemokine that is important in the recruit-
ment of neutrophils (Figure 1I). We also found comparable
weight loss in Il22/ and WT mice and similar numbers of
TUNEL-positive apoptotic cells in the intestinal epithelium after
C. difficile infection (Figures S1D–S1F). These results indicate
that deficiency of IL-22 does not affect the extent of intestinal
damage or recruitment of inflammatory cells after C. difficileinfection and suggest that IL-22 contributes to protection against
C. difficile-infection-induced mortality through other host de-
fense mechanisms.
Reduction of Gammaenterobacteria Protects IL-22-
Deficient Mice from Lethality after C. difficile Infection
The observation that Il22/ andWTmice exhibit comparable in-
testinal epithelial damage and inflammatory response after
C. difficile infection suggests that epithelial damage per se is un-
likely to be the main factor that leads to the death of infected
Il22/ mice. Furthermore, similar numbers of C. difficile were
found in the feces of infected Il22/ and WT mice (Figure S1G),
indicating that IL-22 does not protect the host by promoting
clearance of C. difficile in the intestine. In addition, C. difficile
was not detected in the lung or liver of Il22/ mice, indicating
that the increased mortality of Il22/ mice was not caused by
systemic translocation of C. difficile itself (Figure S1H). Analysis
of the gut microbiota by Illumina sequencing of the 16S rRNA
gene revealed that IL-22 deficiency did not significantly alter
the composition of the fecal microbiota in uninfected and
C. difficile-infected mice (Figures S1I–SK, Table S1). We also
found that IL-22 deficiency did not affect the survival rate of
mice infected with a streptomycin-resistant strain of Salmonella
enterica serovar Typhimurium, whose robust colonization re-
quires elimination of commensals by streptomycin treatment
(Figure S1L). We therefore hypothesized that IL-22 might play
an important role in the systemic clearance of translocated
commensal bacteria after C. difficile infection. To test this, we
determined the numbers of commensals in extraintestinal
organs of Il22/ and WT mice before and after C. difficile infec-
tion. Notably, increased numbers of commensals were detected
in all organs tested, despite similar amounts of fecal bacteria in
Il22/ and WT mice (Figure 2A, Figure S1G). Because no signif-
icant differences in bacterial numbers were found between the
organs of uninfected Il22/ and WT mice (Figure 2A), these
results indicate that in the absence of IL-22, C. difficile infection
results in increased numbers of commensals in extraintestinal
tissues. Consistently, the concentrations of serum aspartate
transaminase (AST) and alanine transaminase (ALT), which are
markers of liver damage, were significantly higher in Il22/
mice than in WT mice 3 days after C. difficile infection (Figures
2B and 2C), most likely reflecting tissue damage associated
with increased burdens of translocated bacteria in the liver of
Il22/ mice after C. difficile infection. Collectively, these results
indicate that IL-22 regulates the clearance of translocated intes-
tinal bacteria in extraintestinal organs after C. difficile infection.
To determine the contribution of translocated commensals to
the pathogenesis ofC. difficile infection, we investigated next the
survival rate ofC. difficile-infected Il22/mice in the absence or
presence of ciprofloxacin, an antibiotic that effectively kills many
commensals, but not C. difficile, in vitro (Figure S1M). Quantita-
tive PCR analysis using bacterial-group-specific primers
showed that ciprofloxacin treatment reduced the numbers of
total bacteria and enterobacteria 8-fold and 30-fold, respec-
tively, but it did not affect the numbers ofC. difficile in feces (Fig-
ure 2D). Histological analysis showed that C. difficile infection
induced a similar degree of epithelial damage and submucosal
edema in ciprofloxacin-treated and control mice (Figure S1N),
which is consistent with comparable numbers of C. difficile inImmunity 41, 620–632, October 16, 2014 ª2014 Elsevier Inc. 621
Figure 1. Il22–/– Mice Are More Susceptible to C. difficile Independently of Epithelial Damage and Neutrophil Recruitment
(A) WT mice were infected with 108 cfu of C. difficile by gastric gavage after antibiotic treatment as described in the Supplemental Experimental Procedures. The
amounts of IL-22 in indicated organs from uninfected (0 d, n = 6) andmice infected for 24 hr (1 d, n = 10) were determined by ELISA. SI, small intestine. Results are
representative of three independent experiments.
(B) Survival of Il22/ andWTmice infected with C. difficilewas monitored for 14 days (n = 16 per group). All mice were infected by gastric gavage with 108 cfu of
C. difficile. No additional deaths were observed beyond 5 days after infection.
(C) Representative histology of ceca from Il22/ and WT mice 3 days after infection. Arrows and arrowheads show submucosal edema and epithelial damage,
respectively (2003 magnification). The images are representative of ten mice per group.
(legend continued on next page)
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IL-22-Mediated Systemic Elimination of Pathobiontsantibiotic-treated and untreated mice. Notably, ciprofloxacin
treatment completely rescued Il22/ mice from C. difficile-
infection-induced lethality (Figure 2E). Importantly, ciprofloxacin
treatment dramatically reduced the number of bacteria
translocated in extraintestinal organs after C. difficile infection
(Figure 2F). Furthermore, Illumina sequencing revealed that
ciprofloxacin treatment strongly reduced the number of
Enterobacteriales species in the liver and feces (Figure 2G).
Taken together, these results suggest that translocated
commensal bacteria after C. difficile infection contribute to
the death of Il22/ mice, which can be rescued by cipro-
floxacin treatment to limit the extent of commensal-bacteria
translocation.
Translocation of Specific Species of Pathobionts after
C. difficile Infection Contributes to Lethality in IL-22-
Deficient Mice
To investigate the role of individual bacterial species in
C. difficile-induced disease, we further characterized the com-
position of the bacteria present in the liver of C. difficile-infected
Il22/ mice and isolated dominant bacteria from the organs of
C. difficile-infected mice to assess their pathogenicity. The
most abundant bacteria in the liver after C. difficile infection
were Enterobacteriaceae species (including several belonging
to the Enterobacter cloacae complex), Klebsiella pneumonia,
and Escherichia coli (Figure 2G). These bacteria represented
89% of anaerobically cultivable bacterial species detected as
operational taxonomic units (OTUs) in Figure 2G. In addition,
Lactobacillales species, including Enterococcus faecalis and
Lactobacillus murinus, were identified as the second dominant
(1% of total bacteria) group in the liver after C. difficile infection
(Figure 2G). To evaluate the ability of these dominant bacterial
species to cause lethality, we infected WT mice with individual
bacterial clones by intravenous (i.v.) administration to mimic
bacterial translocation after C. difficile infection. WT mice in-
fected with enterobacterial species isolated from the tissues of
C. difficile-infected Il22/ mice (NI1077, NI1107, NI1078, and
NI1188) died by day 3 after bacterial administration (Figure 3A),
whereas all mice infected with two Lactobacillales species
(NI1079 and NI1118) also isolated from the liver survived (Fig-
ure 3A). Importantly, i.v. administration of the same number of
16S rRNA phylotype-matched enterobacterial strains (NI796
and NI1185) isolated from the mouse feces did not result in
lethality (Figure 3A). These results suggest that pathogenicity
of enterobacterial species is strain dependent. Consistently,
administration of pathobiont strains, but not that of control phy-
lotype-matched strains of Enterobacteriaceae, induced liver
damage, as assessed by ALT and AST concentrations in serum
(Figures 3B and 3C). Collectively, our data suggest that particular
strains of enterobacterial pathobionts that accumulate and(D and E) The overall pathology (D) and epithelial-damage (E) scores are based o
independent experiments.
(F–H) Immune cells isolated from ceca and colons of Il22/ andWTmice (n = 5 p
of cells labeled with anti-CD11b and anti-Ly-6G or anti-CD11b and anti-F4/80 mA
6G+ (neutrophils) or CD11b+F4/80+ (macrophages) are shown. Results are repre
(I) The amounts of CXCL1 in the indicated tissues of Il22/ and WT mice (n = 5
Results are representative of three independent experiments.
Error bars indicate means. *p < 0.05; **p < 0.01; ****p < 0.0001; n.s., not significatranslocate into extraintestinal organs during C. difficile infection
display remarkable lethality once in the circulation.
Enterobacterial Pathobionts Isolated from C. difficile-
Infected Il22–/– Mice Are Resistant to Complement-
Mediated Phagocytosis
The differential ability of individual commensals to induce tissue
damage and lethality in vivo could be due to differences in
cytotoxicity. However, both pathobiont and nonpathobiont
commensal strains showed similar cytotoxicity and cytokine in-
duction in vitro (Figures S2A–S2C). Therefore, we hypothesized
that pathobiont strains possess a unique ability to escape elim-
ination from host tissues. To test this, we determined the survival
of individual commensals after i.v. administration into WT mice.
Comparison of bacterial numbers in the blood, liver, and lung
of infected mice showed that pathobionts had higher survival
rates than control commensal bacterial strains (Figure 4A, Fig-
ure S3A). Moreover, the survival rates of individual commensals
were proportional to their ability to induce host lethality and
organ damage, as revealed by release of AST and ALT into the
circulation after inoculation in mice (Figure 3). These results sug-
gest that pathobionts cause detrimental tissue damage by
evading host protective immunity.
Previous studies have showna critical role for neutrophils in the
elimination of translocated commensals at intestinal sites in the
mouse model of C. difficile infection (Hasegawa et al., 2010; Ha-
segawa et al., 2012). Therefore, we hypothesized that the entero-
bacterial pathobionts isolated from Il22/ mice after C. difficile
infection have the ability to avoid elimination by neutrophils or
other phagocytic cells. Indeed, isolated pathobionts were more
resistant than control phylotype-matched commensal strains to
both killing by neutrophils (Figure 4B) and phagocytosis by mac-
rophages (Figure 4C). To determine more comprehensively the
susceptibility to phagocytosis of translocated pathobionts that
survived in organs such as the liver after C. difficile infection, we
examined the sensitivity to phagocytosis of 100 randomly
selected bacterial clones isolated from the livers and feces of
Il22/ mice 3 days after C. difficile infection. The proportion of
phagocytosis-resistant commensal clones was significantly
higher in the livers of C. difficile-infected Il22/mice than in the
feces of the same mice (Figure S3B). These results suggest that
some translocated commensals are able to evade phagocytosis
and thus survive in the mouse organs after C. difficile infection.
Phagocytosis of bacteria is facilitated by opsonization with im-
munoglobulins (Igs) and complement factors (Noris and Remuzzi
2013). Therefore, we tested the ability of the sera from Rag1/
andC3/mice, which are deficient in Ig production and all com-
plement pathways, respectively (Noris and Remuzzi 2013), to
facilitate phagocytosis of pathobionts and control commensals.
The sera from C3/ mice poorly promoted the phagocytosis ofn the analysis of ceca on day 3 postinfection. Results are representative of five
er group) were analyzed by flow cytometry 2 days postinfection. (F) Percentage
bs are shown. (G and H) Percentage (G) and cell number (H) ± SD of CD11b+Ly-
sentative of two independent experiments.
per group) were determined by ELISA 24 hr postinfection. SI, small intestine.
nt (p > 0.05). See also Figure S1.
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Figure 2. Increased Load of Commensals in the Peripheral Organs of Infected Il22–/– Mice
(A) The number of total cultivable bacteria in spleen, kidney, liver, lung, and feces from Il22/ (n = 9) and WT (n = 8) mice infected with 108 cfu of C. difficile.
Bacterial loads were determined on days 0 and 3 postinfection by plating on nonselective BHI.
(B andC) The concentrations of AST (B) and ALT (C) in sera from Il22/ (n = 12) andWT (n = 10)mice 3 days afterC. difficile infection. Results are representative of
two independent experiments.
(D–G) Il22/mice were treated with 417 mg/kg ciprofloxacin in drinking water or were left alone () after C. difficile infection. (D) The numbers of total bacteria,
enterobacteria, and C. difficile in feces of ciprofloxacin-treated and untreated control mice (n = 7 per group) on day 2 postinfection were determined by
quantitative RT-PCR. (E) Survival of ciprofloxacin-treated (n = 8) and untreated (n = 7) mice infected with C. difficile was monitored for 14 days. No additional
(legend continued on next page)
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Figure 3. Enterobacteria Isolated from Liver
of Mice Infected with C. difficile Exhibit
Enhanced Lethality after i.v. Administration
Enterobacteriaceae E. hormaechei (Eh) NI1077,
NI1109, and NI796; K. pneumoniae (Kp) NI1078,
NI1188, and NI1185; E. coli NI1076 and K12;
Lactobacillales E. faecalis (Ef) NI1079; and
L. murinus (Lm) NI1118 were administered (23 108
cfu) to WT mice intravenously.
(A) Survival of infectedmice (n = 10) wasmonitored
for 14 days. No additional deaths were observed
beyond 5 days after infection. Results are repre-
sentative of three independent experiments.
(B and C) The concentrations of AST (B) and ALT
(C) in the serum 3 days after infection. Strains
isolated from the liver after C. difficile infection are
indicated in red, whereas control strains (isolates
from the murine intestine and K-12) are indicated
in blue.
Error bars indicate means. *p < 0.05; **p < 0.01.
Results are representative of three independent
experiments. See also Table S1.
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weremore resistant to C3-mediated phagocytosis (Figure 4D). In
contrast, the sera from Rag1/ and WT mice showed a similar
ability to facilitate phagocytosis of both groups of bacteria (Fig-
ure 4D). These results suggest that C3, but not antibodies, is
important for phagocytosis of commensal bacteria. To test
whether pathobionts are less susceptible to complement-medi-
ated phagocytosis by inhibiting either C3 activation or C3 depo-
sition on their surface, we incubated the bacteria in fresh murine
serum as a complement source for 30 min. After incubation, we
detected comparable production of C3 subfragments by immu-
noblotting, suggesting that pathobiont and control bacterial
strains elicit similar complement activation (Figure 4E, lower
panel). To assess the amounts of C3 subfragments deposited
on bacteria, we removed unbound C3 by extensive washing
and immunoblotted bacterial extracts with anti-C3 antibody.
Notably, C3 deposition was lower in pathobionts than in phylo-
type-matched commensals (Figure 4E, upper panel). These re-
sults indicate that pathobionts exhibit a reduced ability to induce
C3 deposition but a similar ability to induce C3 processing.
Similar amounts of bacteria-bound C3 were detected when bac-
teria were incubated with serum fromRag1/ andWTmice (Fig-deaths were observed beyond 5 days after infection. (F) The number of total cultivable bacteria in spleen, kidn
and untreated (n = 8) mice on day 3 infection with C. difficile. Results are representative of two independen
bacteria and cultivable bacterial populations in the liver of ciprofloxacin-treated and untreated mice on day
Error bars indicate means. *p < 0.05; **p < 0.01; ****p < 0.0001; n.s., not significant (p > 0.05). See also Figu
Immunity 41, 620–632ures S3C and S3D), indicating that C3
deposition by commensals is dependent
on the lectin or alternative pathway, but
not the classical Ig-mediated pathway.
To further test which complement
pathway is involved in C3 deposition on
commensal bacteria, we tested the ability
of commensals to bind mannose-binding
lectin (MBL) proteins, which are respon-
sible for C3 deposition in the lectinpathway (Noris and Remuzzi 2013). We found that the tested
commensals did not bind MBL proteins (Figures S3E and S3F),
suggesting that C3 deposition on intestinal bacteria is mediated
by the alternative pathway.
Recombinant IL-22 Improves the Survival of C. difficile-
Infected Mice by Enhancing Systemic Clearance of
Intestinal Pathobionts
Il22/mice showed defective clearance of translocated patho-
bionts in peripheral organs after C. difficile infection (Figure 4A).
We therefore determined whether systemic administration of re-
combinant IL-22 protects Il22/mice from C. difficile-infection-
induced mortality. Intraperitoneal (i.p.) administration of IL-22
rescuedmice frommortality afterC. difficile infection (Figure 5A),
which was associated with reduced numbers of translocated
bacteria in the liver and lung (Figure 5B). To further investigate
the ability of IL-22 to confer systemic protection against patho-
bionts, we used NI1077, one of the dominant pathobionts that
translocate into extraintestinal organs after C. difficile infection.
We found that i.v. administration of pathobiont NI1077 induced
IL-1b production, but no or minimal induction of IL-22 in the liver,
lung, or cecum (Figures S4A–S4E). In contrast, high amounts ofey, liver, and lung from ciprofloxacin-treated (n = 9)
t experiments. (G) Taxonomic composition of fecal
3 after C. difficile infection (n = 2 or 3 per group).
re S2.
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Figure 4. Increased Survival of Enterobacteria in Tissues Is Associated with Impaired Phagocytosis by Neutrophils
(A) WTmice were infected intravenously with 13 108 cfu of E. hormaechei (Eh) NI1077 and NI796; K. pneumoniae (Kp) NI1078 and NI1188; and E. coliNI1076 and
K12. The number of bacteria in the blood from mice (n = 7 per group) on day 2 after infection was determined by plating on BHI media.
(B) Neutrophils were incubated with 5 3 103 cfu of the indicated strains in 2.5% fresh mouse serum for 2 hr. Surviving bacteria were counted by plating on BHI.
(C) Bone marrow macrophages were cultured with the indicated strains at moi 1:1 in the presence of 5% fresh mouse serum. The cells were treated with
gentamycin 20 min after infection. Internalized living bacteria were counted by plating on BHI.
(D) Bone marrow macrophages were cultured with the indicated strains at moi 1:1 in 5% fresh mouse serum from WT, Rag1/, or C3/ mice. The cells were
treated with gentamycin 20 min after infection. Internalized bacteria were counted by plating on BHI.
(E) C3 processing and deposition on indicated strains. A total of 5 3 108 cfu of bacteria were incubated in mouse serum for 30 min, and C3 subfragments
deposited on bacteria (upper panel) and total reaction mixture (lower panel) were detected by anti-C3 antibody. C3 conj, C3 conjugated with bacteria.
Error bars indicate means ± SD. The strains that were isolated from liver after C. difficile infection are indicated in red, whereas control intestinal strains are
indicated in blue. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; n.s., not significant (p > 0.05). Results are representative of four independent experiments. See
also Figure S3.
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robust induction of IL-22 requires intestinal infection in the
C. difficile infection model. To assess the role of IL-22 in protec-
tion against exposures to pathobionts, we intravenously injected
NI1077 into Il22/ and WT mice and found comparable mortal-
ity (Figure S4F). These results suggest that IL-22 protects the626 Immunity 41, 620–632, October 16, 2014 ª2014 Elsevier Inc.host only when robustly induced after C. difficile intestinal infec-
tion. To assess the protective ability of IL-22, we pretreatedmice
with recombinant IL-22 and then intravenously injected NI1077
into Pycard/ mice deficient in C. difficile-infection-induced
production of IL-22 in the intestine (Figures S4G and S4H). We
used Pycard / mice to avoid the induction of IL-22 because
Figure 5. i.p. Administration of Recombi-
nant IL-22 Protects the Host from Systemic
Infection with Pathobionts
(A and B) Il22/ mice were treated with recombi-
nant IL-22 (1 mg per mouse) or mock by i.p. injec-
tion 12 hr after infection with 108 cfu of C. difficile.
(A) The survival of infected mice was monitored for
7 days. No additional deaths were observed
beyond 4 days after infection. Cdiff, C. difficile. (B)
The number of total cultivable bacteria in liver and
lung from Il22/ (n = 10 per group). The bacterial
number in the tissues on day 3 postinfection was
determined by plating on BHI media. Results are
representative of three independent experiments.
(C and D) Pycard/ mice were pretreated with
recombinant IL-22 (1 mg per mouse) (n = 6) or mock
(n = 10) by i.p. injection 1 day prior to i.v. infection
with 2 3 108 cfu of the pathobiont NI1077. (C) The
survival of NI1077-infectedmicewasmonitored for
7 days. No further deaths were observed beyond
4 days after infection. (D) The bacterial number in
blood on day 1 postinfection was determined by
plating on BHI media (n = 5 per group).
*p < 0.05; **p < 0.01. Results are representative
of three independent experiments. See also Fig-
ure S4.
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required for IL-22 production in the liver and lung after i.v. admin-
istration of NI1077 (Figures S4A–S4C). Notably, administration of
recombinant IL-22 improved the survival of NI1077-infected
Pycard/ mice, which was associated with reduced numbers
of NI1077 in the blood (Figures 5C and 5D). These results sug-
gest that IL-22 protects the host by inducing systemic immune
responses that promote the clearance of harmful pathobionts
and thus leads to improved host survival after C. difficile
infection.
IL-22 Enhances Elimination of Commensal Bacteria
during C. difficile Infection by Inducing C3 Expression
and Deposition
To determine the mechanisms by which IL-22 enhances the host
protective response against translocated pathobionts after
C. difficile infection, we first tested the expression of b-defensins
DEFB4 and DEFB14, whose human homologs are induced by IL-
22 stimulation in keratinocytes (Wolk et al., 2004). We found
increased Defb4 mRNA expression in the cecum after
C. difficile infection but undetectable Defb14 mRNA expressionImmunity 41, 620–632in WT and Il22/mice (Figure S5A). Neu-
trophils isolated from Il22/ andWTmice
showed similar bactericidal activity (Fig-
ure S5B), indicating that IL-22 does not
affect the bactericidal activity of neutro-
phils. To further study the immune re-
sponses elicited by IL-22, we reviewed
the Gene Expression Omnibus data set
(accession numbers GDS3226 and
GSE44091) of gene expression in IL-22-
treated or TcdA- and TcdB-treated mu-
rine intestines (Zheng et al., 2008; D’Auriaet al., 2013). In addition to showing increased expression of
genes known to be induced by IL-22, such as those encoding
S100 proteins and acute phase proteins (Liang et al., 2010; Son-
nenberg et al., 2012), analysis of the data sets revealed
increased expression of C3 in IL-22-treated and TcdA- and
TcdB-treated mice (Figures S5C and S4D). Therefore, we deter-
mined whether IL-22 regulates the induction of C3 expression in
response to C. difficile infection. Quantitative RT-PCR analyses
showed that the mRNA expression of C3, but not Cfd (comple-
ment factor D, a component of the alternative complement
pathway), was increased in the liver and intestine 2 days after
C. difficile infection (Figures 6A and 6B). We also confirmed
the induction of other known IL-22-regulated genes after
C. difficile infection, including those encoding S100 proteins
and acute phase proteins (Figures S5E–S5H). Notably, the in-
duction of C3 was significantly lower in Il22/mice than in con-
trol WT mice (Figures 6A and 6B). We also found that the
induction of C3 was independent of RAG1 (Figure S5I). Further-
more, injection of recombinant IL-22 induced C3mRNA expres-
sion in WT mice (Figure 6C) and increased the expression of C3
in the liver of Il22/ mice after C. difficile infection (Figure 6A)., October 16, 2014 ª2014 Elsevier Inc. 627
Figure 6. IL-22 Controls C. difficile-Infection-Induced C3 Expression and Bacterial Deposition
(A and B) Il22/ and WTmice were infected with 108 cfu of C. difficile. The expression of C3 and CfdmRNAs in liver (A) and cecum (B) of Il22/ (n = 12) and WT
(n = 19) mice on day 0 () and day 2 postinfection was determined by quantitative RT-PCR. Cdiff, C. difficile.
(C) WT mice (n = 5 per group) were treated with or without recombinant IL-22 (1 mg per mouse) by i.p. injection. C3 expression in liver was determined by
quantitative RT-PCR.
(D) C3 deposition on the indicated bacterial strains was detected as described in Figure 4 after incubation with sera from Il22/ and WT mice infected (+) or
uninfected () with C. difficile. Cdiff, C. difficile; C3 conj, C3 conjugated with bacteria.
(legend continued on next page)
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Immunity
IL-22-Mediated Systemic Elimination of PathobiontsWe additionally performed immunoblotting analysis to verify that
C3 amounts in serum were also increased in C. difficile-infected
WT and Il22/mice (Figure S5J). Comparison of C3 expression
in organs revealed the liver as the potential major source of
increasedC3 after IL-22 treatment (Figure S5K). Indeed, stimula-
tion of the human hepatocyte cell line HepG2 with IL-22
increased C3 expression, which was inhibited by incubation
with the STAT3-specific inhibitor WP1066 (Figure S5L). In addi-
tion, the amounts of C3 deposition on pathobionts were higher
when the bacteria were incubated with sera from infected WT
mice than when they were incubated with sera from uninfected
WT mice (Figure 6D, compare lanes 1 and 2; 4 and 5; and 7
and 8). Moreover, C3 deposition by pathobionts was lower
when the bacteria were incubated with sera from infected
Il22/ mice than when they were incubated with sera from in-
fected WT mice (Figure 6D, compare lanes 2 and 3; 5 and 6;
and 8 and 9). Likewise, the bactericidal activity of neutrophils
was enhanced by incubation with sera from C. difficile-infected
WT mice, but not from Il22/ mice (Figure 6E). Furthermore,
the sera from mice treated with IL-22 enhanced both C3 deposi-
tion on pathobionts (Figure 6F) and the bactericidal activity of
neutrophils (Figure 6G). These results indicate that IL-22 pro-
motesC3 expression and deposition on bacteria and thereby en-
hances the ability of neutrophils to kill pathobionts.
To determine the role of C3 in IL-22-mediated protective re-
sponses, we determined the effect of C3 depletion by cobra
venom factor (CVF) on the ability of serum to augment patho-
biont killing by neutrophils. Immunoblotting analysis showed
that C3 amounts in the serum were increased after IL-22 treat-
ment (Figures S5M and S5N). Injection of CVF depleted C3 in
naive and infected mice after treatment with IL-22 (Figure S5N).
Notably, C3 depletion by CVF was confirmed by the disappear-
ance of the C3 peak in the chromatographic profile and of the C3
a chain in Coomassie blue staining (Figures S5M and S5N, lower
panel), indicating that C3 is highly abundant in the serum, consis-
tent with the published serum-protein database (Nanjappa et al.,
2014). Because IL-22 can potentially induce multiple serum pro-
teins, we separated serum proteins by UnoQ column chroma-
tography and determined whether the C3-containing fraction
would specifically augment pathobiont killing by neutrophils.
Immunoblotting analysis showed that C3 was separated from
most of other serum proteins and was detected in fraction 3 (Fig-
ures S5M and S5N). The serum from IL-22-treated mice showed
increased protein amounts in fraction 3 as well as in other frac-
tions, whereas CVF-treated mice with and without IL-22
coinjection showed reduced protein amounts only in fraction 3
(Figure S5M), consistent with the finding by Coomassie blue
staining. Using UnoQ column fractionation, we found that the
presence of C3 (fraction 3) correlated with increased pathobiont
killing activity by neutrophils, which was enhanced by IL-22 and
blocked by C3 depletion with CVF (Figure S5O). Therefore, C3,(E) Neutrophils were incubated with the indicated strains in mouse sera from Il22
were counted by plating on BHI. Cdiff, C. difficile.
(F and G) WT mice were treated with or without recombinant IL-22 (1 mg per mo
detected after incubation with sera fromWTmice treated with recombinant IL-22
indicated strains with mouse sera from WT mice treated with or without recomb
Error bars indicate means ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001;
experiments. See also Figure S5.but not other abundant serum proteins, appears to be particu-
larly important for pathobiont-killing activity by neutrophils. To
determine whether C3 is important for host mortality and bacte-
rial elimination after C. difficile infection and i.v. injection of the
pathobiont NI1077, we treated mice with CVF to deplete C3
before C. difficile infection or pathobiont i.v. administration. We
found that CVF-treated mice were more susceptible to both
C. difficile infection (Figure S5P) and i.v. administration of the
pathobiont (Figure S5R). Importantly, IL-22 injection failed to
rescue CVF-treated mice from mortality induced by i.v. adminis-
tration of the pathobiont (Figure S5R). Consistently, we found
that bacterial load was higher in the liver and lung of
C. difficile-infected mice that had been pretreated with CVF (Fig-
ure S5Q) and in the blood of pathobiont-infected mice than in
mice pretreated with CVF or mice without CVF treatment (Fig-
ure S5S). Collectively, these results suggest that C3 plays an
important role in IL-22-mediated pathobiont elimination during
C. difficile infection and protects the host from pathobiont-
induced lethality.
DISCUSSION
In this study, we have demonstrated a protective role for IL-22 in
host defense against C. difficile infection. Il22/mice displayed
higher mortality than did WT mice after C. difficile infection
despite a comparable degree of intestinal damage and pathogen
burden. In Il22/ mice after C. difficile infection, we found
increased translocation of enterobacterial pathobionts to extra-
intestinal organs, including the liver, which was associated with
increased degree of liver injury. These pathobionts exhibited
high pathogenicity when present in the blood, which was asso-
ciated with their resistance to complement-mediated phagocy-
tosis and killing by phagocytes. Importantly, IL-22 was required
for induction of C3 after C. difficile infection, and IL-22 adminis-
tration protected the mice from pathobiont accumulation in
extraintestinal organs and pathobiont-associated mortality.
Therefore, our study highlights an important role for IL-22 in
limiting pathobiont-induced systemic disease and identifies a
mechanism by which pathobionts can evade host immunity.
IL-22 has been shown to be critical for host defense against
other pathogens (Aujla et al., 2008; Basu et al., 2012; Satoh-
Takayama et al., 2008; Schulz et al., 2008). In addition, IL-22
has been implicated in the clearance of Alcaligenes species in
lymphoid tissues (Sonnenberg et al., 2012) and affects the
composition of the microbiota in mice infected with S. enterica
Typhimurium (Behnsen et al., 2014). However, we found no
significant differences between Il22/ mice and WT mice in
the microbiota composition before or after C. difficile infection,
suggesting that IL-22 does not regulate the composition of mi-
crobiota in all infection models. In other infection models, IL-22
protects the host against pathogens via the induction of/ and WT mice infected or uninfected with C. difficile. The surviving bacteria
use) by i.p. injection. (F) C3 deposition on the indicated bacterial strains was
. C3 conj, C3 conjugated with bacteria. (G) Neutrophils were incubated with the
inant IL-22. The survival of bacteria was assessed by plating on BHI.
n.s., not significant (p > 0.05). Results are representative of three independent
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IL-22-Mediated Systemic Elimination of Pathobiontsantimicrobial peptides, such as RegIII proteins, and enhances
the repair of the intestinal epithelium, at least in part, by prevent-
ing epithelial cell death (Brandl et al., 2007; Zheng et al., 2008).
Deficiency in IL-22 also results in increased translocation of in-
testinal bacteria into the liver after C. rodentium infection.
Although IL-22 protects the host by regulating the elimination
of C. rodentium (Basu et al., 2012), IL-22 did not affect the num-
ber of C. difficile in the intestine. This suggests that IL-22 can
also promote host survival through mechanisms distinct from
pathogen elimination. Our studies highlight the importance of
systemic protection against pathobionts after they are translo-
cated into peripheral organs as a result of intestinal epithelial bar-
rier defects induced by C. difficile infection. In the C. difficile
infection model, IL-22 plays a critical role in complement-medi-
ated elimination of pathobionts that have disseminated system-
ically, at least in part, by upregulating C3 expression. Therefore,
IL-22 protects the host not only by promoting intestinal barrier
function but also by promoting protective systemic immune re-
sponses. In theC. difficile infection model, inflammasome-medi-
ated IL-1b production is also critical for both local (intestinal) and
systemic immune responses by facilitating neutrophil recruit-
ment and promoting elimination of commensals after
C. difficile infection (Hasegawa et al. 2011; Hasegawa et al.
2012). IL-1b is also important for IL-22 production by innate
lymphoid cells (Sutton et al., 2009). It is possible that the host
has additional protective mechanisms against infection to link
local to systemic immune responses against pathogens and
pathobionts. Moreover, C. difficile infection induces several pro-
teins, including S100 proteins and acute phase proteins, in an IL-
22-dependent manner. S100 proteins are known to regulate C3
expression (Schonthaler et al., 2013). Therefore, S100might also
contribute to increased C3 expression during C. difficile infec-
tion. C3 activation by bacteria results in production of C3a and
the downstream factor C5a (Noris and Remuzzi 2013). C3a
and C5a are known to be involved in the recruitment of IL-
1b-producing inflammatory cells, inflammasome activation,
and IL-22 induction (Liu et al., 2011; Laudisi et al., 2013; Noris
and Remuzzi 2013). Therefore, innate responses mediated by
complement fragments IL-1b and IL-22 might exert a positive-
feedback loop as a part of the complex host defensemechanism
that confers both intestinal and systemic protection against
pathobiont-induced morbidity. Complement fragments and IL-
22 are also known to be involved in liver repair (Strey et al.,
2003; Radaeva et al., 2004). Therefore, signaling mediated by
complements IL-1b and IL-22 might also play an important role
during the recovery phase after C. difficile infection. Fully under-
standing the mechanisms by which the host coordinates local
and systemic immunity will require additional studies.
After C. difficile infection, a subset of patients with pseudo-
membranous colitis develop sepsis and multiple organ failure,
which are associated with high mortality (Eaton and Mazuski,
2013; Sunenshine andMcDonald, 2006). The elimination of com-
mensals by antibiotics improves host survival after C. difficile
infection in the mouse model, suggesting a potential therapeutic
application. C. difficile possesses toxins that disrupt epithelial
barrier function (Kuehne et al., 2010), which subsequently leads
to translocation of commensals and immunostimulatory mole-
cules through the damaged intestinal epithelium. Neutrophils
that are recruited into the damaged intestine can eliminate630 Immunity 41, 620–632, October 16, 2014 ª2014 Elsevier Inc.many of the translocated commensals after C. difficile infection
(Hasegawa et al., 2011; Hasegawa et al., 2012). However, we
have shown here that certain pathobionts are resistant to host
defense responses, including phagocytosis, and eventually
translocate into peripheral organs to cause organ damage.
Therefore, host mechanisms to boost systemic protection
against translocated pathobionts, such as those mediated
through IL-22, are important for survival against C. difficile infec-
tion and could be exploited in the treatment against C. difficile
infection. Our study has shown that g-enterobacterial commen-
sals as one of the dominant pathobionts responsible for compli-
cations of C. difficile infection in the mouse model. Importantly,
individual strains within the same g-enterobacterial species
display differential sensitivity to complement-mediated phago-
cytosis and cause varying degrees of lethality to the host. One
of the complement-resistance mechanisms exhibited by bacte-
ria is capsular polysaccharides (CPSs) on the bacterial surface,
which can shield bacteria from recognition by complement fac-
tors (Rautemaa and Meri, 1999). In addition, the outer structures
of lipopoly(oligo)saccharides (LPSs or LOSs) are crucial for pro-
tecting bacteria against host immune responses, including com-
plement activity (Roberts, 1996). The complement-resistant
structural determinants of CPSs and LPSs are highly diverse
among enterobacteria (Rautemaa and Meri, 1999). Therefore,
the differential sensitivity of individual strains within the same
bacterial species to complement might be ultimately dependent
on their surface structures. Our study highlights the importance
of complement resistance in the pathogenesis of commensal-
mediated intestinal disease. Therefore, understanding themech-
anisms by which pathobionts acquire complement resistance
will be critical for treating systemic complications caused by
gut commensal bacteria. The presence of commensals is impor-
tant to suppress C. difficile expansion in the intestine, and
elimination of competitive commensals by antibiotics results
in overgrowth of C. difficile and C. difficile-infection-related dis-
ease (Carroll and Bartlett, 2011). Currently, elimination of
C. difficile with vancomycin and/or metronidazole is the first-
line treatment for C. difficile-infected patients (Rupnik et al.,
2009). However, some patients suffer relapsing disease that is
refractory to standard antibiotic treatment. Transplantation of
fecal microbiota from healthy donors has been shown to be
effective for the prevention of disease recurrence (Koenigs-
knecht and Young, 2013; Lo Vecchio and Cohen, 2014).
Because individual strains within the same species possess dif-
ferential resistance against host elimination and can give rise to
varying degrees of disease severity, it will be important to assess
in detail the composition of the donor microbiota in fecal trans-
plants to avoid transplanting potential pathobionts to patients
already sickened by infection and dysbiosis.EXPERIMENTAL PROCEDURES
Bacterial Strains
C. difficile VPI10463 and E. coli K-12 were cultured as previously described
(Hasegawa et al., 2012). Enterobacter hormaechei NI1077, NI1109, and
NI796; Klebsiella pneumoniae NI1078, NI1188, and NI1185; E. coli NI1076;
E. faecalis NI1079; and L. murinus NI1118 were isolated from the intestine of
C. difficile-infected or uninfected mice and cultured at 37C in brain heart infu-
sion (BHI) medium (BD) under an aerobic environment, and their 16S rRNA
gene phylotypes were determined as described in Hasegawa et al. (2012).
Immunity
IL-22-Mediated Systemic Elimination of PathobiontsMice
WT, C3/, and Rag1/ C57BL/6 (B6) mice were obtained from the Jackson
Laboratory. Il22/mice in B6 backgroundwere a gift fromDr.Wenjun Ouyang
(Genentech). All mice were housed, bred, and maintained under specific path-
ogen-free conditions as described in Hasegawa et al. (2012). Mice in different
cages or derived fromdifferent sourceswere cohoused for 2weeks for normal-
ization of the microbiota composition before experiments. The mouse studies
were approved by the University of Michigan Committee on Use and Care of
Animals.
C. difficile Infection and Analyses
Eight-week-old mice were infected with 108 colony-forming units (cfu) of
C. difficile VPI10463 after antibiotic treatment as described in Hasegawa
et al. (2012). Postinfection analyses were performed as described in the Sup-
plemental Experimental Procedures.
Analysis of Microbiota Composition
Bacterial DNAs were extracted from mouse intestines as described in Hase-
gawa et al. (2012). The V4 region of the 16S rRNA gene (252 bp) was
sequenced with an Illumina MiSeq sequencer, and z22,000 reads were
analyzed byMothur (Schloss et al., 2009; Kozich et al., 2013). OTUs were clas-
sified into taxonomic phylotypes at >97% identity with the use of Mothur
(Schloss et al., 2009).
Preparation of Intestinal Immune Cells and Flow Cytometric
Analysis
Intestinal lamina propria cells were prepared from mice 2 days postinfection,
and immunostaining and flow cytometric analysis were performed as previ-
ously described in Hasegawa et al. (2012). In brief, isolated lamina propria cells
were stained with fluorescein-isothiocyanate-labeled CD11b monoclonal anti-
body (mAb; M1/70), allophycocyanin-labeled mAb F4/80 (BM8), and phycoer-
ythrin-labeled Ly-6G mAb (1A8). Isotype-matched antibodies (BD) were used
as controls. Dead cells were excluded with 7-AAD staining. Neutrophils
were defined as CD11b+Ly-6G+ cells, and macrophages were defined as
CD11b+F4/80+ cells.
Assay of Systemic Infection
Mice were injected with 2 3 108 cfu of isolated commensals intravenously.
Bacterial number in the blood on day 3 was determined by serial plating of
diluted blood, and colonies were counted on BHI plates after 24 hr incubation
under aerobic conditions.
Assay of Phagocytosis and Bacterial Killing
Bone-marrow-derived macrophages were cultured with isolated bacteria
(multiplicity of infection [moi] 1:1) for 20 min with or without 5% fresh
mouse serum and then treated with 50 mg/ml gentamycin for 1 hr after five
washes with PBS. The cells were lysed with 0.1% Nonidet P-40 in PBS
and plated on BHI. Under these conditions, 91% ± 3% of bacteria survived
in macrophages for 2 hr, and 97.2% ± 0.7% of bacteria were killed within
24 hr. For the assay of bacterial killing, mouse peritoneal neutrophils were
collected from the i.p. cavity 4 hr after i.p. injection of thioglycollate medium.
Next, 5 3 105 neutrophils were incubated with 5 3 103 bacteria with 2.5%
(v/v) fresh mouse serum for 2 hr. Bacterial survival was assessed by plating
on BHI.
Immunoblotting for C3 Deposition
A total of 53 108 bacteria were incubated in 50% (v/v) mouse serum for 30min
at 37C. Unbound C3 was removed from bacterial pellets by washing with ice-
cold PBS. Samples and control 1/200 total reaction mixtures were boiled in
Laemmli’s buffer and separated by 10% SDS-PAGE (1 3 108 bacteria per
lane). For C3 deposition, C3 was examined by immunoblotting using anti-
mouse C3d antibody (R&D). For the binding assay of MBL proteins, MBLs
were examined by immunoblotting using anti-mouse MBL1 and MBL2 anti-
bodies (gifts from Steffen Thiel, Aarhus University in Denmark). For equal
loading, aliquots from each sample were plated, and equal amounts of
colony-forming units were lysed.Statistical Analysis
Statistical analyses were performed with GraphPad Prism software version 6.0
(GraphPad Software). Differences between two groupswere evaluated with an
unpaired two-tailed Student’s t test. False discovery rate q values were calcu-
lated by Mothur (Schloss et al., 2009) for comparison of OTU abundances. For
multiple group comparisons, statistical analysis was performed with one-way
ANOVA and then the Dunnett’s or Sidak’s test as a post hoc test. The survival
rate of infected mice was analyzed with the log-rank test. Differences at
p < 0.05 were considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
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